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PFS. Monthly resource utilisation associated with PFS and pro-
gression was estimated by a consensus panel of UK experts. Cost
of AEs and drug-administration costs were also included. The
evaluation accounted for longer treatment duration (24%) with
erlotinib compared to docetaxel (mean duration 125 vs. 101
days, respectively). The incremental drug acquisition cost for
erlotinib vs docetaxel was consequently £1867. The primary
outcome was total direct NHS costs and QALYs. RESULTS:
Total direct NHS costs were £12,701 and £12,621 for erlotinib
and docetaxel, respectively. Erlotinib vs docetaxel offers a cost
saving of £971/patient due to its oral administration and
£301/patient in the management of AEs. QALYs were 0.201 
and 0.176 (erlotinib vs docetaxel, respectively). The ICER for
erlotinib vs docetaxel was estimated at £3354. Erlotinib was
cost-effective whether or not the calculation assumed improve-
ments in PFS. Improvements in QoL and reduced toxicity with
erlotinib led to greater total QALYs vs docetaxel. CONCLU-
SIONS: Erlotinib is a valuable alternative to docetaxel in
relapsed NSCLC. Efﬁcacious without compromising QoL and
well tolerated, erlotinib can be considered a highly cost-effective
treatment for NSCLC in the UK. Orally administered, it may also
be associated with a capacity beneﬁt to the NHS through reduc-
tion in existing infusion and outpatient requirements.
HEALTH CARE USE & POLICY STUDIES
HP1
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OBJECTIVES: The large availability of economic evaluations
and their increasing importance for decision making emphasizes
the need for economic evaluations that are methodologically
sound. The aim of this study is to provide users of economic
evaluations of cholesterol lowering drugs with an insight into the
quality these evaluations. By focussing on the most relevant
studies the gap between research and policy making may be nar-
rowed. METHODS: A systematic review was conducted. All
publications on economic evaluations of cholesterol lowering
drugs were identiﬁed by searching Pub Med, the Centre for
Reviews and Dissemination database (CRD), the National
Health Service Economic Evaluation Database (NHS EED), the
Health Technology Assessment database (HTA) and the Data-
base of Abstracts of Reviews of Effects (DARE). A search strat-
egy was set up to identify the articles to be included. These
articles were quality assessed using Drummond’s checklists. The
scoring was performed by at least two reviewers. When neces-
sary, disagreement between these reviewers was decided upon in
a consensus meeting. We calculated an average quality score for
the included articles. RESULTS: The search identiﬁed 23 articles
that were included. Most studies measured the costs/LYG. The
overall score per study varied between 2.7 and 7.7 with an
average of 5.4. Most studies score high on the measurement of
costs and consequences whereas the establishment of effective-
ness leaves room for improvement. Only two studies included a
well performed incremental analysis. CONCLUSION: This
review noticed an increase of quality of economic evaluations
over time. Consequently, the value of cost-effectiveness studies
for policy decisions increases over time. In general piggy back
evaluations tend to score higher on quality and are therefore
more valuable in decisionmaking.
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OBJECTIVES: ARBs were introduced into the UK antihyper-
tensive drug market with conﬂicting data on their relative effec-
tiveness compared to other classes, which offered lower cost
alternatives. The study aim was to determine patient-level char-
acteristics of ARB prescribing patterns and how these changed
over time since the ﬁrst ARB market launch December 1994.
METHODS: The study population was identiﬁed from the
Health Improvement Network (THIN) database, an electronic
medical record dataset of patients seen by general practitioners
in the UK. Patients who received an oral drug approved for
hypertension treatment at any point in time from 1995 through
2003 were included. The multinomial logit model was applied
to two time periods to predict the likelihood of receiving an ARB
prescription compared to other antihypertensive drug classes,
after controlling for patient characteristics. A time dummy tested
for changes between the time periods. RESULTS: Immediately
after the ﬁrst ARB introduction (1995–1997), 0.25% (N =
537,309) of the study population was allocated to ARB therapy.
This rose to 6.22% (N = 803,981) for the more recent time
period (2001–2003). In the early time period, patients with high
blood pressure readings and patients seen by a Cardiologist were
more likely to receive prescriptions for ARBs than other antihy-
pertensive classes. This did not persist for the more recent time
period. Over time, prescribing antihypertensive drugs for
patients with diabetes shifted away from all classes (P < 0.01),
except the angiotensin converting enzyme inhibitor (ACEi) class
(P = 0.6334), towards ARB prescribing. For patients with heart
failure, there was a statistically signiﬁcantly shift away from pre-
scribing ARBs towards the beta-blocker and “Other” classes. In
general, patients with diabetes or heart failure were more fre-
quently prescribed ACEi than ARB therapy. CONLUSIONS:
ARBs were prescribed cautiously in the UK and ARB prescrib-
ing patterns altered over time as new safety and effectiveness evi-
dence emerged.
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OBJECTIVES: To describe the role of general practitioners (GPs)
in the initial management of women with UI in 4 European coun-
tries with different health care systems. METHODS: Cross-
sectional community postal survey of 2,953 community-dwelling
women with UI in France, Germany, Spain and the UK.
RESULTS: There was an overall response rate of 53% (n =
1573). Forty eight percent had discussed their UI with a doctor.
More women discussed UI in France and Germany than in the
UK and Spain. The patient usually raised the issue, during con-
sultations for some other reason. Fear of, or actual deterioration
in UI was the most important reason for discussing UI. Overall
52% of incontinent women ﬁrst discussed their UI with a GP
and almost a third of women reported having all their UI dis-
cussions in a GP setting. Twenty nine per cent of women reported
that GPs had either recommended treatment or monitoring of
their condition before beginning treatment and 24% reported
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that the GP had referred them to another doctor for evaluation
and treatment. Most women in the UK ﬁrst discussed UI with a
GP whereas in Germany most discussed UI with a specialist. In
Spain and France about half the women ﬁrst discussed their UI
with a GP. CONCLUSIONS: GPs are involved to varying degrees
in the initial management of UI in France, Germany, Spain 
and the UK. Even in countries where women have a choice of
whether to see a GP or specialist about UI many choose to have
their ﬁrst contact with a GP.
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OBJECTIVES: Summary measures of population health (SMPH)
are used by national governments and international agencies 
for comparative purposes. Such measures have other uses, for
example, in monitoring changes in health status over time. Com-
peting approaches for calculating SMPH have been developed
using different metrics: disability-adjusted life years (DALY) and
quality-adjusted life years (QALY). This lack of standardization
in approach might produce conﬂicting results. The present study
was designed to measure disease burden in a US national popu-
lation survey (MEPS) to test both approaches. METHODS: Two
methods are compared here: ﬁrst, the health expectancy method,
computing health-adjusted life expectancy by combining health
related quality of life (HrQoL) and survival data; second, the
health gap method, measuring disease burden by combining the
losses due to premature mortality and non-fatal conditions. Both
EQ-5D social preference weights and Global Burden of Disease
disability weights are employed to assess the effect of different
scoring systems. Four disease areas were studied: diabetes,
stroke, coronary heart disease (CHD) and asthma. RESULTS:
Using the health expectancy method based on EQ-5D values, the
highest QALY loss of 3.67 years per person was associated with
CHD, followed by diabetes (1.26), stroke (1.15) and asthma
(0.57). The results based on disability weights had the same rank
order among diseases but varied in magnitude by between 1%
and 42% compared to EQ-5D estimates. Results were similar
using the health gap method. Disability-weighted estimate for
CHD was 8508 thousand DALYs, followed by diabetes (4378),
stroke (3277) and asthma (1429); EQ-5D values produced the
same rank order but variation was lower (2% to 15% lower).
CONCLUSIONS: A single metric for measuring health status in
clinical and population studies would help improve knowledge
transfer between health care decision-makers. EQ-5D has poten-
tial value as a summary measure of population health.
INFECTION
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OBJECTIVES: Pneumococcal (Pnc) disease represents a major
health care concern being associated with severe complications.
Scope of this study was to evaluate the budgetary impact effect
of providing vaccination with seven-valent pneumococcal 
conjugate vaccine (PCV) to newborns in Lombardy (Italy).
METHODS: Budget impact analysis was applied to the 2004
cohort of newborns of Lombardy: efﬁcacy data as number of
pneumonia and acute otitis media (AOM) cases, and consump-
tion of resources were derived from a large multicenter single-
blind clinical study (results published) of vaccinated versus
unvaccinated Italian children. Vaccinated children were adminis-
tered 3 doses of PCV at 3, 5 and 11 months of age; Pnc morbid-
ity was recorded until the 30th month of age. Economic analysis
was performed in the perspective of the third party payer, con-
sidering direct costs (vaccine doses, administration costs, drugs,
visits and hospitalisations for management of Pnc disease com-
plications); unit cost of resources (2006 values) was retrieved from
national reimbursement tariff lists and other published sources.
RESULTS: The cost of vaccination was calculated as €133/
patient; cost of pneumonia and AOM were calculated as €2258
and €31 per case. Vaccination of the whole newborns population
of Lombardy would avoid about 6700 cases of AOM and 2700
cases of pneumonia. The economic effect of vaccination would
be a net saving, ranging from €million 1.0 to 0.8 and 0.5 for
respectively 100%, 80% and 50% vaccination coverage. These
savings may be underestimated when considering the economic
effects on cases of meningitis, the extension of vaccination bene-
ﬁts after the second year of age in the vaccinated infants and the
effect of herd immunity on total population. CONCLUSION:
Our analysis suggests that the use of PCV in infants is likely to
be economically justiﬁed due to savings from pneumonia and
AOM cases averted, in the population of newborns of Lombardy.
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OBJECTIVES: Indicators to measure the quality of health care
are increasingly being developed and used both by health care
professionals and policy makers. In the context of increasing
costs related to antimicrobial use and resistance we aimed to
develop valid antibiotic prescribing quality indicators for 
ambulatory care, producible on the basis of present ESAC
(www.ua.ac.be/ESAC) data on antibiotic utilisation.
METHODS: Experts from 15 countries participating in a Euro-
pean Science Foundation workshop in September 2005 proposed
a set of 24 indicators and subsequently scored these indicators
for their relevance to controlling antimicrobial resistance, patient
health beneﬁt, prescription cost-effectiveness and public health
policy making using a scale ranging from 1 (= completely dis-
agree), over 5 (= uncertain) to 9 (= completely agree). The scores
were processed according to the UCLA-RAND appropriateness
method and each indicator was judged valid if there was con-
sensus and the median score was not within the 1–6 interval.
RESULTS: Twenty-two participants scored. Nine indicators
were rated as valid antibiotic prescribing indicators on all four
dimensions and three extra for their relevance at least to pre-
scription cost-effectiveness. The 2004 indicator values of a valid
set of 12 quality indicators of cost-effective antibiotic utilsation
are available for 28 individual countries. The most informative
indicator “total outpatient use” varied more than threefold
between the countries with the highest (33.4 DDD per 1000
inhabitants per day (DID) in Greece) and lowest (9.2 DID in
Russia) use. CONCLUSIONS: In line with the main objectives
of antimicrobial use surveillance at the European level, this
subset can be used to describe antibiotic use in ambulatory care
in order to assess the quality of antibiotic prescribing and its
cost-effectiveness. The indicator values allow individual coun-
tries to position themselves and to deﬁne their own benchmark,
